Precision BioSciences is a clinical-stage biotechnology company focused on developing in vivo gene editing therapies for genetic diseases. They leverage their proprietary ARCUS genome engineering platform to create novel therapies that aim to correct disease-causing mutations within a patient's own cells. Their lead product candidate, PBCAR0191, is being developed for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r ALL) and non-Hodgkin lymphoma (NHL). The company also has a strategic collaboration with TG Therapeutics for the development of a CAR T therapy for multiple sclerosis.
